Avacta Group Share News (AVCT)

Avacta denies press speculation over potential fundraising

(Sharecast News) - Oncology drug developer Avacta Group responded to recent market speculation over a potential fundraising initiative on Monday.

LONDON MARKET OPEN: Stocks falter amid weaker outlook for China

(Alliance News) - Stock prices in London opened lower on Monday, ahead of more interest rate decisions, and amid fears for China's slowing economic recovery.

LONDON BRIEFING: Severn Trent deal sized up by CMA; Coca-Cola HBC buys

(Alliance News) - Stocks in London are called lower on Monday, ahead of more central bank decisions, while a meeting between US Secretary of State Antony Blinken and his Chinese counterpart put relations between the two nations back under the spotlight.

Avacta triggers second milestone payment in AffyXell venture

(Sharecast News) - Life science company Avacta Group announced on Monday that a second milestone equity payment had been triggered, resulting in an increased shareholding for Avacta in AffyXell Therapeutics.

Avacta sees shares rise on new equity payment for South Korea venture

(Alliance News) - Avacta Group PLC on Monday celebrated "rapid" progress on its joint venture in South Korea, following a second equity payment.

Avacta buys Belgium-based Coris Bioconcept for £7.4m

(Sharecast News) - Life science company Avacta Group announced the acquisition of Coris Bioconcept for initial cash consideration of £7.4m on Thursday.

Avacta enhances rapid test portfolio with GBP7.4 million Coris buy

(Alliance News) - Avacta Group PLC on Thursday said that it has bought Coris Bioconcept SRL, adding a range of professional-use rapid tests to its product portfolio.

TRADING UPDATES: Volex wins contract; Engage XR revenue jumps

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Avacta doses first patient in US tumour treatment trial

(Sharecast News) - Oncology and diagnostics developer Avacta announced the dosing of the first patient in the United States under its investigational new drug (IND) application on Thursday - a milestone for its first therapeutic product 'AVA6000', based on its proprietary 'preCISION' technology.

EARNINGS SUMMARY: hVIVO sees 30% revenue growth; Next 15 lifts payout

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Revenue rises, adjusted EBITDA loss improves for Avacta

(Sharecast News) - Oncology-focussed drugs and diagnostics developer Avacta reported full-year revenue of £9.7m in its preliminary results on Tuesday, up from £2.9m year-on-year.

UK earnings, trading statements calendar - next 7 days

Avacta presents pre-clinical data for anti-cancer candidate

(Sharecast News) - Life science company Avacta Group announced the presentation of pre-clinical data for its novel 'preCISION' proteasome inhibitor AVA3996 on Monday.

Avacta opens first two clinical investigator sites in US for AVA6000

(Alliance News) - Avacta Group PLC on Thursday said it opened its first two clinical investigator sites for the phase 1 clinical trial of AVA6000 on Wednesday, under it US investigational new drug application.

Avacta opens first US clinical investigator sites

(Sharecast News) - Life sciences company Avacta has opened its first two clinical investigator sites in the US for a Phase 1 clinical study on its AVA6000 candidate.